文献速递免疫规划传染病防控与疫情报告

mRNA新冠疫苗与灭活流感疫苗同时或序贯接种的免疫原性随机临床试验

Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial.
PubMed 文献 · Vaccine · 2025-12-10

美国多中心随机试验纳入335名≥5岁参与者,比较mRNA新冠疫苗与四价灭活流感疫苗同时接种或间隔7-14天序贯接种的免疫原性。结果显示,同时接种组与序贯接种组针对 ancestral D614G 株和 BA.4/5 变异株的 SARS-CoV-2 中和抗体几何平均滴度无显著差异(p=0.79 和 p=0.69)。结论认为同时接种未观察到 mRNA 新冠疫苗免疫原性减弱。

要点

  • 同时接种 mRNA 新冠疫苗与 IIV4 未减弱针对 D614G 和 BA.4/5 的中和抗体应答。
  • 同时接种组与序贯组抗体滴度差异无统计学意义(p=0.79 和 p=0.69)。
  • 该随机试验支持≥5岁人群同时接种 mRNA 新冠疫苗与灭活流感疫苗。

核心结论

  • mRNA 新冠疫苗与流感疫苗同时接种未观察到免疫原性减弱。

研究设计与样本

  • 美国多中心随机临床试验,335名≥5岁参与者随机接受同时接种或序贯接种。
  • 同时接种组 mRNA 新冠疫苗与四价灭活流感疫苗(IIV4)同一天接种。
  • 序贯接种组先接种 mRNA 新冠疫苗,7-14天后接种 IIV4。

主要发现

  • 同时接种组157人,序贯接种组150人。
  • 接种后针对 ancestral D614G 株的 SARS-CoV-2 ID50 几何平均滴度:同时组4357.1 vs 序贯组4492.3(p=0.79)。
  • 针对 BA.4/5 变异株的几何平均滴度:同时组1547.8 vs 序贯组1463.8(p=0.69)。

临床怎么用

  • 预防接种门诊可考虑对≥5岁人群同时接种 mRNA 新冠疫苗与灭活流感疫苗,无需间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A U.S. multisite trial was conducted and explored whether blunting of mRNA COVID-19 vaccine immunogenicity occurred when administered simultaneously with influenza vaccine. METHODS: Persons ≥5 years of age received either quadrivalent inactivated influenza vaccine (IIV4) or saline placebo simultaneously with an initial or booster dose of mRNA COVID-19 vaccine. Those receiving placebo with mRNA COVID-19 vaccine received IIV4 7-14 days later. SARS-CoV-2 antibody was assessed by pseudovirus neutralization (D614G, BA.4/BA. 5, and XBB.1.5) at baseline and 28 days following mRNA COVID-19 vaccine primary series or booster dose. RESULTS: Of 335 randomized participants, 157 were in the simultaneous group and 150 the sequential group. Post-vaccination geometric mean SARS-CoV-2 ID50 titers for the ancestral D614G strain and BA.4/5 variant (simultaneous versus sequential) were 4357.1 versus 4492.3(p = 0.79) and 1547.8 versus 1463.8(p = 0.69), respectively. CONCLUSION: Blunting of mRNA COVID-19 vaccine immunogenicity was not observed when mRNA COVID-19 and influenza vaccines were administered simultaneously. TRIAL REGISTRATIONClinicalTrials.gov ID: NCT05028361.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Walter EB, Schlaudecker EP, Talaat KR, et al. Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial. Vaccine. 2025. PMID: 41380398. doi:10.1016/j.vaccine.2025.128072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。